Evidence map›Paper›PMID 36290822›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes.

Zheng Zhang, Nanfang Huang, Feng Xv, Sida Zhao, Juan Guo, Youshan Zhao, Chunkang Chang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zheng ZhangDepartment of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Nanfang HuangDepartment of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Feng XvDepartment of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Sida ZhaoDepartment of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Juan GuoDepartment of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Youshan ZhaoDepartment of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.ORCID 0000-0003-3363-4766
Chunkang ChangDepartment of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndrome is one of the main hematological malignancies that threaten the health of the elderly. However, biomarkers which predict the progression and prognosis of MDS are still controversial and puzzling. FOXO1 gene plays an important role in a variety of intracellular functions, including tumor suppression and cellular immune regulation. However, there is no research report on the correlation between FOXO1 and the clinical features of MDS including immune environment. In this study, we observed that FOXO1 expression is associated with neutrophil count, blasts, chromosome and different MDS scoring systems. FOXO1 expression is closely related to MDS cell immune polarization, and the increase expression of FOXO1 is significantly related to the amplification of immune cell polarization ratio. In addition, FOXO1 expression is associated with progression-free survival and overall survival in MDS patients. Moreover, in a multivariate model FOXO1 low-expression was an independent predictor of poor survival in MDS. In summary, FOXO1 may play a candidate tumor suppressor in MDS, and FOXO1 is a useful independent prognostic predictor in MDS, and it may provide a candidate target therapy in future.

Indexed as

Myelodysplastic SyndromesAgedBiomarkersForkhead Box Protein O1HumansPrognosisBiomarkersForkhead Box Protein O1FOXO1 protein, humanFOXO1immunitymyelodysplastic syndromesprognosis

Identifiers

PMID36290822
PMCPMC9600488
OpenAlexW4297150762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.